Pharmacovigilance: Towards a better understanding of the benefit to risk ratio

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 2, 2002, Pages

  Simon, L S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

CONFERENCE PAPER; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STOMACH ULCER; UNITED STATES;

EID: 0036839328     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.suppl_2.ii88     Document Type: Conference Paper

References (6)

1. Edlavitch SA. Post marketing surveillance methodologies. Drug Intell Clin Pharm 1988;22:68-78.
2. Shapiro S. The epidemiological evaluation of drugs. Acta Med Scand Suppl 1984;683:23-7.
3. Strom BL. Overview of different logistical approaches to post marketing surveillance. J Rheumatol Suppl 1988;17:9-13.
4. Leiper JM, Lawson DH. Why do doctors not report adverse drug reactions? Neth J Med 1985;28:546-50.
5. Strom BL, Melmon KL, Miettinen OS. Post marketing studies of drug efficacy. Arch Intern Med 1985;145:1791-4.
6. Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: A comparison. J R Soc Med 1991;84:341-4.